Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(23)00681-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
Eur J Cancer
December 2024
International Breast Cancer Center, Quirónsalud Group, Barcelona, Spain; IOB Madrid, Hospital Beata Maria Ana, Madrid, Spain; Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas & Co, Jersey City (New Jersey, USA), Sao Paulo, Brazil; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
Objective: DESTINY-Breast03, a randomised, phase 3 trial, evaluated trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor (HER2)-positive unresectable and/or metastatic breast cancer who progressed on or after treatment with trastuzumab and a taxane. At the current data cut off overall survival analysis, T-DXd demonstrated a substantial improvement in overall survival over T-DM1. This secondary analysis use of DESTINY-Breast03 aimed to further evaluate the treatment differences using quality-adjusted survival time without symptoms or toxicity (Q-TWiST) methods.
View Article and Find Full Text PDFThe value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China.
Front Pharmacol
July 2024
Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Background: Breast cancer (BC) is one of the most common cancers worldwide. The inevitability of drug resistance to initial anti-HER-2 therapy necessitates the emergence of second-line anti-HER-2 drugs which exhibit a promising outlook. Consequently, it is imperative to appraise their efficacy through network meta-analysis and ascertain their comparative cost-effectiveness.
View Article and Find Full Text PDFTrastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
Cancer Sci
September 2024
Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. Here, we report a subgroup analysis of Asian patients enrolled in DESTINY-Breast03.
View Article and Find Full Text PDFConcurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials.
ESMO Open
July 2024
Department of Radiation Oncology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan.
Article Synopsis
- Trastuzumab deruxtecan (T-DXd) showed significantly better effectiveness compared to trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive metastatic breast cancer in the DESTINY-Breast03 study, with a follow-up of 41 months.
- The results revealed a median progression-free survival (PFS) of 29.0 months for T-DXd versus 7.2 months for T-DM1, along with improved overall survival (OS) of 52.6 months compared to 42.7 months.
- Safety profiles were consistent with earlier data, and no new severe cases of interstitial lung disease or pneumonitis were observed, indicating that
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!